ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2007 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 26, 2007--ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30 pm ET on Thursday, May 3, 2007 to discuss the Company's financial results for the three-month period ended March 31, 2007 - the third quarter of ImmunoGen's 2007 fiscal year. Management also will provide an update on the Company.
To access the live call by phone, dial 913-981-4900. No passcode is required. The call also may be heard through the Investor Relations section on the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through May 10, 2007.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Companies licensing the right to develop anticancer compounds to specific targets using ImmunoGen's TAP technology include Biogen Idec, Biotest AG, Centocor (Johnson & Johnson), Genentech, and sanofi-aventis. Three anticancer compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-MCC-DM1, in development by Genentech.
CONTACT:
ImmunoGen, Inc.
Carol Hausner
Executive Director, Investor Relations and Corporate Communications
Tel: 617-995-2500
info@immunogen.com
